



## LUMIGAN<sup>®</sup> Fact Sheet

### About LUMIGAN<sup>®</sup> (bimatoprost ophthalmic solution) 0.03%

LUMIGAN<sup>®</sup> was originally approved by the U.S. Food and Drug Administration (FDA) in 2001 for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant or insufficiently responsive to other IOP-lowering medications. In 2006, LUMIGAN<sup>®</sup> was approved by the FDA as a first-line treatment for elevated IOP associated with open-angle glaucoma or ocular hypertension and is now used as an initial treatment in an increasing number of patients. LUMIGAN<sup>®</sup> monotherapy delivers effective and sustained IOP lowering.<sup>1,2</sup>

### How LUMIGAN<sup>®</sup> Works

One of the risk factors of glaucoma is elevated IOP, or pressure inside the eye. LUMIGAN<sup>®</sup> therapy is thought to lower elevated IOP by enhancing the outflow of aqueous humor, the fluid in the eye that fills the space between the back surface of the cornea and the front of the lens, helping it drain through two separate path ways out of the eye. This dual method of outflow makes LUMIGAN<sup>®</sup> ophthalmic solution an effective therapy to lower elevated IOP and help manage glaucoma.

### LUMIGAN<sup>®</sup> Key Benefits

- LUMIGAN<sup>®</sup> ophthalmic solution offers an easy once-a-day dosing regimen. Maintaining once-daily dosing can be convenient for patients.<sup>3</sup>
- LUMIGAN<sup>®</sup> has broad formulary and Medicare Part D coverage.<sup>4</sup>

### LUMIGAN<sup>®</sup> Efficacy

In clinical studies of patients with open-angle glaucoma or ocular hypertension with a mean baseline IOP of 26 mm Hg, the IOP-lowering effect of LUMIGAN<sup>®</sup> (bimatoprost ophthalmic solution) 0.03% once daily (in the evening) was 7-8 mm Hg.<sup>5</sup>

### About Glaucoma

Glaucoma, a group of eye diseases characterized by damage to the optic nerve, is the leading cause of preventable blindness in the United States.<sup>6</sup> It is estimated that three million Americans have glaucoma, but only half of those know they have it.<sup>7</sup> The total number of glaucoma cases worldwide is estimated to be 65 million.<sup>7</sup> One of the risk factors of glaucoma is elevated IOP, or pressure inside the eye. A healthy eye produces fluids, called aqueous humor, at the same rate fluids are drained. If the aqueous humor is not removed rapidly enough or the eye fills too rapidly, pressure builds up in the eye, which can result in glaucoma. This high pressure distorts the shape and damages the optic nerve. Maintaining healthy IOP levels may slow the progression of the disease and help prevent loss of vision.



-more-

### **Important LUMIGAN® Safety Information**

LUMIGAN® ophthalmic solution has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN® is used. After stopping LUMIGAN®, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond five years are not known. When only one eye is treated, there is a possibility of eyelash changes in the eye treated with LUMIGAN® ophthalmic solution. These changes may result in differences between the eyes in eyelash length, thickness, darkness, number of eyelashes and/or direction of eyelash growth. The most common side effects of LUMIGAN® ophthalmic solution are eye redness, growth of eyelashes and itchy eyes. Please refer to full [prescribing information](#).

###

### **Additional Information**

For more information about LUMIGAN® ophthalmic solution, please refer to the full [prescribing information](#) and the product Web site at [www.lumigan.com](http://www.lumigan.com).

**Contact:**     **Heather Katt**  
Allergan, Inc.  
(714) 246-6224  
[katt\\_heather@allergan.com](mailto:katt_heather@allergan.com)

® Marks owned by Allergan, Inc.

---

<sup>1</sup> Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. *Amer J Ophthalmol* 2003; 135(1):55-63.

<sup>2</sup> Higginbotham EJ, Schuman JS, Goldberg I, et al, for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. *Arch Ophthalmol*. 2002; 120(10):1286-1293.

<sup>3</sup> Mansukani SS. Improving adherence to drug-treatment regimens for glaucoma. *P&T Digest*. November 29, 2003; 49-53.

<sup>4</sup> Pinsonault. Formulary Position by Product. August 2007.

<sup>5</sup> LUMIGAN™ prescribing information.

<sup>6</sup> The Glaucoma Foundation. "TGF Urges Eye Exams to Detect the Disease Early." January 8, 2006. Available at: [http://www.glaucomafoundation.org/news\\_story.php?i=38](http://www.glaucomafoundation.org/news_story.php?i=38). Accessed April 19, 2007.

<sup>7</sup> Glaucoma Research Foundation. "Glaucoma Facts and Stats." Available at: [http://www.glaucoma.org/learn/glaucoma\\_facts.html](http://www.glaucoma.org/learn/glaucoma_facts.html). Accessed: July 31, 2007.